Biotech Stocks

Global Blood Therapeutics (GBT) Gets Attention of FDA As Well As Investors

Monday morning Global Blood Therapeutics (GBT) announced the FDA has agreed to GBT’s plan to file for accelerated approval of voxelotor, a unique …

Analyst Predicts Success for Catalyst Pharmaceutical (CPRX ) Stock Following News of Latest FDA Approval

Catalyst Pharmaceutical (CPRX) stock fell about 8% between Thursday and Friday. Even though the company just announced its first FDA approval for Firdapse, …

Cowen Analyst Goes All in For Vertex (VRTX) Stock

Vertex (VRTX) is Cowen analyst’s top large-cap pick for the second year in a row. That’s how Phil Nadeau put it while increasing …

What New Information is Causing This Bull to Charge Ahead for Amarin (AMRN) Stock?

The Amarin (AMRN) saga is not over yet. Following a somewhat dramatic couple of weeks after the release of the biopharmaceutical’s drug, Vascepa, analysts …

Top Analyst Stands Firm for Acadia Pharmaceutical (ACAD) Stock While its Anti-Depression Medication Goes Through Trial

After a series of talks with depression key opinion leaders (KOL) about Acadia Pharmaceutical’s (ACAD) Ph2 CLARITY trial, all four experts believe the …

Stemline Therapeutics (STML) Gets One Step Closer to EMA Approval; Analyst Weighs in With U.S. Angle

Stemline Therapeutics (STML) announced the European Medicines Agency (EMA) is granting accelerated assessment for the company’s marketing authorization for oral treatment, Elzonris. The …

Cowen Analyst Bullish On Vertex (VRTX) Stock After Company Releases Favorable Data

Biopharmaceutical Vertex’ (VRTX) is working on a trial called Phase III VX-659 and Cowen analyst Phil Nadeau calls some recently released data “Good …

Why Does this Analyst Slash His Price Target in Half — Right Before Launch of Paratek Pharmaceuticals’ (PRTK) Drug NUZYRA?

Paratek Pharmaceuticals (PRTK) is preparing to launch its drug NUZYRA, following FDA approval granted on October 2nd. The medication treats both community-acquired bacterial …

Should You Pull the Trigger on Nektar (NKTR) Stock Following Updated Melanoma Data?

Nektar Therapeutics (NKTR) presented some updated results on Friday, November 9th from the melanoma expansion cohort of Phase II from PIVOT-02 study. The cancer-focused …